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Methods: This was a prospective observational study carried out at
a single tertiary care centre of north India. Sequential patients who
presented with STEMI and at least 1 or more lesions ≥70% in a
major epicardial vessel other than the infarct-related artery
were included. Patients who underwent primary PCI or PCI after
thrombolysis were included. Patients were assigned to 3 different
strategies: culprit vessel angioplasty-only (COR); staged revascu-
larization (SR); and simultaneous treatment of non-IRA (CR).
Results: A total of 109 patients of acute ST elevation MI were
enrolled during a period of 6 months. The mean age was 55.38
 10.0 years, 84 (77.0%) weremen. The COR group included 48 (44%)
patients, the SR group 44 (40%) and the CR group 17 (16%). The
elective PCI in the SR group was performed on average 58  20days
after the initial PCI. After a mean follow-up of 6 months, 9 (8%)
patients died, 3 (2.6%) from cardiac causes. Throughout the follow-
up, 32 (30%) patients experienced at least 1 MACE, 14 (45.0%) in the
COR group, 8 (25.0%) in the SR group and 10 (30%) in the CR group,
p < 0.001. The incidence of inhospital death, repeat revasculariza-
tion and re-hospitalization was signiﬁcantly higher in the COR
group (all p < 0.05), whereas there was no signiﬁcant difference in
re-infarction among the 3 groups. A total of 2 patients (1 each in the
SR and CR group) received both a re-PCI and a subsequent CABG.
Survival free of re-PCI was worse in the COR group compared with
both the CR ( p < 0.001) and the SR group ( p < 0.005), whereas it was
similar between the CR and SR groups ( p < 0.467). Mortality was
more frequent in the COR group although it did not reach statistical
signiﬁcance. The COR group showed a tendency for a worse overall
survival compared with the other groups, without reaching statis-
tical signiﬁcance ( p < 0.151).
Conclusion: Culprit vessel-only PCI was associated with highest
rate of long-term MACE compared with multivessel treatment.
Patients scheduled for staged revascularization experienced a
similar rate of MACE to patients undergoing simultaneous treat-
ment of non-IRA.
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Intra aortic balloon pump (IABP) is an important short term LV
mechanical assist device in patientswith acute LVdysfunction and
cardiogenic shock of varying etiology like acute MI, acute myocar-
ditis, acute valvular regurgitation secondary to infective endiocar-
ditis etc. Recently published 1ABP-SHOCK II trial showed that IABP
in acute MI setting in Intensive Coronary Care Unit (ICCU) does not
have any mortality advantage. In this study, we have studied the
outcome of patients who underwent IABP insertions in our hospi-
tal due to various indications.
Aims and objective: To study the outcome of patients who under-
went IABP insertion in ICCU settings.
Material and methods: We retrospectively analyzed the data of
patients who received IABP insertion in our ICCU due to various
indications during January 2014–December 2014. We studied the
clinical details, indications of IABP insertion, complications and
their outcome. The outcome was noted in terms of all cause
mortality in ICCU, all causemortality during or after surgery during
index hospitalization and survival till discharge.
Results: During the above mentioned period, 35 patients under-
went IABP insertion out of which 26 (74.29%) were male, and
9 (25.71%) were females. Mean age of study population was 56
years. 33 (94.29%) patients came with acute STEMI, 1 (2.86%) had
myocarditis and 1 (2.86%) patient had acute severe MR secondary
to infective endocarditis. Out of 33 patients with STEMI, 17 (51.52%)
patients had cardiogenic shock due to pump failure, 6 (18.19%)
patients had post MI acute VSD, 4 (12.12%) patients had acute
ischemic severe MR, 2 (6.06%) patients had refractory ventricular
arrhythmias and 4 (12.12%) patients had refractory angina despite
full medical antianginal support.
17 (51.52%) patients had altered renal function in terms of
increased blood urea and serum creatinine before IABP insertion.
Average duration of IABP insertion was 2.3  1.2 days. During IABP
insertion, 9 (52.94%) patients developed leucocytosis, 3 (17.65%)
patients had anemia (1 required blood transfusion), 3 (17.65%)
patients had thrombocytopenia. Out of 17 patients who had
deranged renal function, 13 (76.47%) patients continued to have
renal dysfunction and 4 (23.53%) patients improved. However, 8
(47%) patients developed new onset renal dysfunction on IABP. 8
(22.86%) patients on IABP developed puncture site complications (3
had hematoma, 2 had limb ischemia and 3 had CVA). However
except for one patient with hematoma who required BT, all others
were managed conservatively. Out of 35 patients, 20 (57.14%)
patients died during index hospitalization (14 before surgery and
6 after surgery). 14 (40%) patients died in ICCU before they could
have been operated (pump failure-10, MI + VSD-3, MI + MR-1). One
patient of myocarditis was managed conservatively. Remaining 14
patients underwent surgery. During post surgery stay 6 (17.14%)
patients died (3 CABG patients, 2 CABG + VSD repair, ICABG
+ MVR). Out of 17 patients with deranged renal function on admis-
sion, 14 (82.35%) died.
Conclusion: Cardiogenic shock in acute MI setting continues to
have high mortality despite IABP support. Patients with impaired
renal function on admission are at particularly at higher risk for
mortality.
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Introduction: Left ventricular assist devices (LVADs) were origin-
ally developed as a temporary bridge to heart recovery and then
approved as bridge to Heart Transplant for End stage heart failure
patients falling in INTERMACS category 1, 2, and 3. Successful
outcomes with these indications justiﬁed usage of LVADs as des-
tination therapy. We report our initial experience on a series of 9
patients implanted with LVAD as destination therapy who were
either unsuitable for transplant or due to non-availability of sui-
table heart when patients were sick or as patient's choice with 4
months to 3 years follow-up.
Patient proﬁle: The hospital records of 11 patients implanted with
LVAD between Nov 2012 and Dec 2014 were retrospectively ana-
lyzed. There were 8 males and 3 females with age ranging from 26
to 51 years (mean – 47 years). 2 models of LVADs were implanted –
HEARTMATE–II (Thoratec-Axial Flow) in 3 patients and HEART-
WARE (HVAD – Centrifugal ﬂow) in 8 patients. Heart Mate 2 (infra-
diaphragmatic pocket) was chosen for body weight more than
70 kg and HEART WARE for low body weight patients (intraper-
icardial pocket, smaller device).
Basic diagnoses and clinical condition: Out of 11 patients 4 had
ischemic cardiomyopathy, one had recent anterior myocardial
infarction with recurrent VT and LV dysfunction, one had severe
valvular aortic stenosiswith severe LV dysfunction and other 3 had
dilated cardiomyopathy with severe heart failure. Other 2 patients
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